Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7162258 | 0.89 | KDM4E (0.47) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL9216581 | 0.85 | KDM4E (0.64) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL23411350 | 0.82 | KDM4E (0.64) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL29891520 | 0.82 | KDM4E (0.64) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL6231890 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL13469508 | 0.80 | TDP1 (0.48) | ALDH1A1KDM4ELMNAHPGDHTT | |
| SCHEMBL568368 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL30099730 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL6232947 | 0.78 | GRM2 (0.47) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL6208525 | 0.77 | MEN1 (0.60) | ALDH1A1KDM4EMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401443-A4 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORP (US) | 2005-10-26 | — | — | EP | claimed |
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | claimed |
| EP-1401443-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | claimed |
| WO-2002098424-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | claimed |
| EP-1401443-A4 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORP (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | disclosed |
| EP-1401443-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002098424-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147739-A1 | Novel anti-infectives | RPL5, RPL7, RPL35 | ALDH1A1 1494/4885KDM4E 4266/4885MEN1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.